Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Cosman, Felicia, Crittenden, Daria B., Adachi, Jonathan D., Binkley, Neil, Czerwinski, Edward, Ferrari, Serge, Hofbauer, Lorenz C., Lau, Edith +9 more·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1607948

Cited by (1,001)

Items 201–300 of 1,001

Romosozumab in osteoporosis: yesterday, today and tomorrow
Dong Wu, Lei Li, Zhun Wen, Guangbin Wang · 2023 · Journal of Translational Medicine
Pharmacological Therapy of Osteoporosis: What’s New?
Giovanni Iolascon, Antimo Moretti, Giuseppe Toro, Francesca Gimigliano, Sara Liguori, Marco Paoletta · 2020 · Clinical Interventions in Aging
Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk
Cy W. Fixen, Jennifer Tunoa · 2021 · Current Osteoporosis Reports
Bone-Vascular Axis in Chronic Kidney Disease
Pieter Evenepoel, Britt Opdebeeck, Karel David, Patrick C. D’Haese · 2019 · Advances in Chronic Kidney Disease
Romosozumab for the treatment of osteoporosis
McClung, Michael R. · 2018 · Osteoporosis and Sarcopenia
Osteoporosis: Current and Emerging Therapies Targeted to Immunological Checkpoints
Massimo De Martinis, Maria Maddalena Sirufo, Lia Ginaldi · 2019 · Current Medicinal Chemistry
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
Jacques P. Brown, Klaus Engelke, Tony M. Keaveny, Arkadi A. Chines, Roland D Chapurlat, A. Joseph Foldes, Xavier Nogués, Roberto Civitelli, Tobias De Villiers, Fabio Massari et al. · 2021 · Journal of Bone and Mineral Research
Focal adhesion protein Kindlin-2 regulates bone homeostasis in mice
Huiling Cao, Qinnan Yan, Dong Wang, Yumei Lai, Bo Zhou, Qi Zhang, Wenfei Jin, Simin Lin, Yiming Lei, Li‐Ting Ma et al. · 2020 · Bone Research
Sclerostin in chronic kidney disease–mineral bone disorder think first before you block it!
Vincent Matthias Brandenburg, Anja Verhulst, Anne Babler, Patrick C. D’Haese, Pieter Evenepoel, Nadine Kaesler · 2018 · Nephrology Dialysis Transplantation
NOTUM inhibition increases endocortical bone formation and bone strength
Robert Brommage, Jeff Liu, Peter Vogel, Faika Mseeh, Andrea Y. Thompson, David Potter, Melanie K. Shadoan, Gwenn M. Hansen, Sabrina L. Jeter-Jones, Jie Cui et al. · 2019 · Bone Research
Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application
Martina Rauner, Hanna Taipaleenmäki, Elena A. Tsourdi, Elizabeth Martha Winter · 2021 · Journal of Clinical Medicine
Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
Stéphanie Fabre, Thomas Funck‐Brentano, Martine Esther Cohen-Solal · 2020 · Journal of Clinical Medicine
Male osteoporosis
Leonardo Bandeira, Barbara Campolina Carvalho Silva, John Paul Bilezikian · 2022 · Archives of Endocrinology and Metabolism
Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
Antonio Naranjo, Petra Díaz del Campo Fontecha, María Pilar Aguado Acín, Luis Marcelino Arboleya Rodríguez, E. Casado, Santos Castañeda, Jordi Fiter Aresté, Laia Gifre, Carmen Gómez Vaquero, Gloria Candelas et al. · 2018 · Reumatología Clínica
Sclerostin and Vascular Pathophysiology
Antonino Catalano, Federica Bellone, Nunziata Morabito, Francesco Corica · 2020 · International Journal of Molecular Sciences
Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations
Jingbo Xie, Jian Guo, Zaeema Kanwal, Mingzheng Wu, Xiangyang Lv, Nihal Abdalla Ibrahim, Ping Li, Manal Ali Buabeid, El‐Shaimaa A. Arafa, Qingshan Sun · 2020 · International Journal of Endocrinology
Management of Osteoporosis and Spinal Fractures: Contemporary Guidelines and Evolving Paradigms
Nasvin Imamudeen, Amjad Basheer, Anoop Mohamed Iqbal, Nihal Manjila, Nisha Nigil Haroon, Sunil V. Manjila · 2022 · Clinical Medicine & Research
Therapeutic Antibodies in Medicine
Prerna Sharma, Rahul V. Joshi, Robert Pritchard, Kevin Xu, Maya A. Eicher · 2023 · Molecules
Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway
Natasha M. Appelman‐Dijkstra, Socrates E. Papapoulos · 2018 · Nature Reviews Endocrinology
An overview of the management of osteoporosis in the aging female population
Usman Amin, Aoife McPartland, Miriam O’Sullivan, Carmel Silke · 2023 · Women s Health
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old
Nicholas R. Fuggle, Andrea Laslop, René Rizzoli, Nasser M. Al‐Daghri, Majed Saleh Alokail, Ewa Bałkowiec-Iskra, Charlotte Beaudart, Olivier Bruyère, Angie Botto‐van Bemden, Nansa Burlet et al. · 2025 · Drugs
ACOG Clinical Practice Guideline No. 2: Management of Postmenopausal Osteoporosis
Swan Sim Yeap, FL Hew, S-P Chan · 2022 · Obstetrics and Gynecology
Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study
Gianluca Tenore, Angela Zimbalatti, Federica Rocchetti, Francesca Graniero, Domenico Gaglioti, Ahmed Mohsen, Martina Caputo, Marco Lollobrigida, Luca Lamazza, Alberto De Biase et al. · 2020 · Journal of Clinical Medicine
Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project
Richard Eastell, Eric Vittinghoff, Li‐Yung Lui, Charles E. McCulloch, Imre J. Pavo, Arkadi A. Chines, Sundeep Khosla, Jane A. Cauley, Bruce Mitlak, Douglas C. Bauer et al. · 2020 · Journal of Bone and Mineral Research
Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases
Frank Buttgereit, Andriko Palmowski, Milena Bond, Giovanni Adami, Christian Dejaco · 2024 · Nature Reviews Rheumatology
Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial
Joy N. Tsai, Hang Lee, Natalie L. David, Richard Eastell, Benjamin Z. Leder · 2019 · The Lancet Diabetes & Endocrinology
Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential
Michael R. McClung · 2017 · Therapeutic Advances in Musculoskeletal Disease
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026
Mandeep Singh Bajaj, Rozalina G. McCoy, Kirthikaa Balapattabi, Raveendhara R. Bannuru, Natalie J. Bellini, Allison K. Bennett, Elizabeth Ann Beverly, Kathaleen Briggs Early, Sathyavathi ChallaSivaKanaka, Justin Basile Echouffo-Tcheugui et al. · 2025 · Diabetes Care
Wnt signaling in bone, kidney, intestine, and adipose tissue and interorgan interaction in aging
Di Chen, Rong Xie, Bing Shu, ALAN L. LANDAY, Changli Wei, Jochen Reiser, Anna Spagnoli, Alfonso Torquati, Christopher B. Forsyth, Ali Keshavarzian et al. · 2018 · Annals of the New York Academy of Sciences
Sclerostin Protects Against Vascular Calcification Development in Mice
Annelies De Maré, Britt Opdebeeck, Ellen Neven, Patrick C. D’Haese, Anja Verhulst · 2020 · Journal of Bone and Mineral Research
Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review
Nyruz Ramadan Elahmer, Sok Kuan Wong, Norazlina Mohamed, Ekram Alias, Kok‐Yong Chin, Norliza Muhammad · 2024 · Biomedicines
Advances in the management of osteoporosis
Caroline Wei Shan Hoong, Dominik Saul, Sundeep Khosla, Jad G. Sfeir · 2025 · BMJ
The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis
Anne Sophie Sølling, Torben Harsløf, Bente Lomholt Langdahl · 2018 · Therapeutic Advances in Musculoskeletal Disease
The crisis of inadequate treatment in osteoporosis
Christian Roux, Karine Briot · 2020 · The Lancet Rheumatology
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
Nicholas R. Fuggle, Cyrus C. Cooper, Nicholas C. Harvey, Nasser M. Al‐Daghri, Maria Luisa Brandi, Olivier Bruyère, Antonio Cano, Elaine Margaret Dennison, Adolfo Díez‐Pérez, Jean‐Marc Kaufman et al. · 2020 · Drugs
Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture
Felicia Cosman · 2020 · Endocrine Practice
Role of nutritional vitamin D in osteoporosis treatment
Yi‐Chou Hou, Chia‐Chao Wu, Min-Tser Liao, Jia‐Fwu Shyu, Chi‐Feng Hung, Tzung‐Hai Yen, Chien‐Lin Lu, Kuo‐Cheng Lu · 2018 · Clinica Chimica Acta
New therapeutic targets for osteoporosis
Panagiotis G. Anagnostis, Nifon K. Gkekas, Michael E. Potoupnis, Eustathios I. Kenanidis, Eleftherios E. Tsiridis, Dimitrios G. Goulis · 2018 · Maturitas
A Review on the Role of Denosumab in Fracture Prevention
Kok-Lun Pang, Nie Yen Low, Kok‐Yong Chin · 2020 · Drug Design Development and Therapy
Drug discovery of sclerostin inhibitors
Sifan Yu, Dijie Li, Ning Zhang, Shuaijian Ni, Meiheng Sun, Luyao Wang, Huan Xiao, Dingdong Liu, Jin Liu, Yuanyuan Yu et al. · 2022 · Acta Pharmaceutica Sinica B
Anabolic therapy for osteoporosis: update on efficacy and safety
Leonardo Bandeira, Edward Michael Lewiecki · 2022 · Archives of Endocrinology and Metabolism
Bone Fragility Fractures in CKD Patients
Ana Pimentel, Pablo Ureña, Jordi Bover, José Luis Fernández Martín, Martine Esther Cohen-Solal · 2020 · Calcified Tissue International
The Role of Sclerostin in Bone Diseases
Elias S. Vasiliadis, Dimitrios-Stergios Evangelopoulos, Angelos Kaspiris, Ioannis S. Benetos, Christos Vlachos, Spyros G Pneumaticos · 2022 · Journal of Clinical Medicine
A Mini Review on Osteoporosis: From Biology to Pharmacological Management of Bone Loss
Kok‐Yong Chin, Ben Nett Ng, Muhd Khairik Imran Rostam, Nur Farah Dhaniyah Muhammad Fadzil, Vaishnavi Raman, Farzana Mohamed Yunus, Syed Alhafiz Syed Hashim, Sophia Ogechi Ekeuku · 2022 · Journal of Clinical Medicine
Pathophysiology of Medication‐Related Osteonecrosis of the Jaw—A Minireview
Sotirios Tetradis, Matthew R. Allen, Salvatore L. Ruggiero · 2023 · JBMR Plus
Cardiovascular Safety and Sclerostin Inhibition
Bente Lomholt Langdahl, Lorenz Christian Hofbauer, John Colin Forfar · 2021 · The Journal of Clinical Endocrinology & Metabolism
Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study
Motohiko Sato, Masaaki Inaba, Shinsuke Yamada, Masanori Emoto, Yoshiteru Ohno, Yoshihiro Tsujimoto · 2021 · Journal of Bone and Mineral Metabolism
Orthogeriatrics
P. Falaschi, David Marsh · 2020 · Practical issues in geriatrics
The Mechanotransduction Signaling Pathways in the Regulation of Osteogenesis
Zhaoshuo Liu, Qilin Wang, Junyou Zhang, Sihan Qi, Yingying Duan, Chunyan Li · 2023 · International Journal of Molecular Sciences
A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause
Tracy E. Madsen, Talia Sobel, Seraphina Negash, Tara A. Shrout, Marcia L. Stefanick, JoAnn E. Manson, Matthew Allison · 2023 · International Journal of Women s Health
Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region
Manju Chandran, Paul Mitchell, Tanawat Amphansap, Sanjay Kumar Bhadada, Manoj D. Chadha, Ding‐Cheng Chan, Yoon‐Sok Chung, Peter Robert Ebeling, Nigel Leslie Gilchrist, Aysha Habib Khan et al. · 2021 · Osteoporosis International
An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines
John А. Kanis, Helena Johansson, Nicholas C. Harvey, Mattias Lorentzon, Enwu Liu, Liesbeth Vandenput, Eugene Vincent McCloskey · 2021 · Osteoporosis International
T -Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
Felicia Cosman, Edward Michael Lewiecki, Peter Robert Ebeling, Eric Hesse, Nicola Napoli, Toshio Matsumoto, Daria B. Crittenden, Maria Rojeski, Wenjing Yang, Cesar R. Libanati et al. · 2020 · Journal of Bone and Mineral Research
Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab
Steven R. Cummings, Charles E. McCulloch · 2020 · Osteoporosis International
Treatment Sequence for Osteoporosis
Felicia Cosman, Bente Lomholt Langdahl, Benjamin Z. Leder · 2024 · Endocrine Practice
Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials
Yue Liu, Yan Cao, S Zhang, W. Zhang, Bin Zhang, Q. Tang, Zhigang Li, Junyan Wu · 2018 · Climacteric
Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots
Yuanyu Qiu, Wu Yang, Qijin Wang, Sijia Yan, Bo Li, Xiao Zhai · 2018 · Archives of Osteoporosis
Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture
Mohit Bhandari, Emil H. Schemitsch, Theofilos S. Karachalios, Parag Kantilal Sancheti, Rudolf Wilhelm Poolman, John N Caminis, Nadia S Daizadeh, Ricardo E. Dent-Acosta, Ogo I. Egbuna, Arkadi A. Chines et al. · 2020 · Journal of Bone and Joint Surgery
The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density
Anna C. van der Burgh, Catherine E. de Keyser, M. Carola Zillikens, Bruno H. Ch. Stricker · 2021 · Drugs
Bone fragility and osteoporosis in children and young adults
Melissa M. Formosa, María Christou, Outi Mäkitie · 2023 · Journal of Endocrinological Investigation
Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate
Kamyar Asadipooya, Ada Weinstock · 2019 · Arteriosclerosis Thrombosis and Vascular Biology
Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
Akimitsu Miyauchi, Rajani V. Dinavahi, Daria B. Crittenden, Wenjing Yang, Judy Maddox, Etsuro Hamaya, Yoichi Nakamura, Cesar R. Libanati, Andreas Grauer, Junichiro Shimauchi · 2019 · Archives of Osteoporosis
Multiple Myeloma and Bone: The Fatal Interaction
Silvia Marino, G. David Roodman · 2017 · Cold Spring Harbor Perspectives in Medicine
Medication‐related osteonecrosis of the jaw: A literature review and update
Shinichiro Kuroshima, Farah A. Al‐Omari, Muneteru Sasaki, Takashi Sawase · 2022 · genesis
Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys
Rogely Waite Boyce, Qing‐Tian Niu, Michael S. Ominsky · 2017 · Bone
Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis
Sara Kaveh, Hossein Hosseinifard, Nashmil Ghadimi, Mahdi Vojdanian, Aidin Aryankhesal · 2020 · Clinical Rheumatology
WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer
Else Driehuis, Hans C. Clevers · 2017 · British Journal of Pharmacology
Transplantation of Noncultured Stromal Vascular Fraction Cells of Adipose Tissue Ameliorates Osteonecrosis of the Jaw–Like Lesions in Mice
Shinichiro Kuroshima, Muneteru Sasaki, Kazunori Nakajima, Saki Tamaki, Hiroki Hayano, Takashi Sawase · 2017 · Journal of Bone and Mineral Research
Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss
Man‐Hai Liu, Pam Kurimoto, J. Zhang, Qing‐Tian Niu, Marina Stolina, Paul C. Dechow, Jian Q. Feng, Jacob Y. Hesterman, M.D. Silva, Michael S. Ominsky et al. · 2018 · Journal of Dental Research
The cytoskeleton and connected elements in bone cell mechano-transduction
Nicole R. Gould, Olivia M. Torre, Jenna M. Leser, Joseph P. Stains · 2021 · Bone
Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study
Tomonori Kobayakawa, Takako Suzuki, Masaki Nakano, Makoto Saito, Akiko Miyazaki, Jun A. Takahashi, Yukio Nakamura · 2021 · Bone Reports
Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone
Kristian F. Axelsson, Anna G Nilsson, Hans Wedel, Dan Lundh, Mattias Lorentzon · 2017 · JAMA
Globular adiponectin reverses osteo-sarcopenia and altered body composition in ovariectomized rats
Shyamsundar Pal China, Subhashis Pal, Sourav Chattopadhyay, Konica Porwal, Sapana Kushwaha, Sharmishtha Bhattacharyya, Monika Mittal, Anagha Ashok Gurjar, Tarun Kumar Barbhuyan, Abhishek K. Singh et al. · 2017 · Bone
Monoclonal antibodies for treating osteoporosis
Maria Felicia Faienza, Mariangela Chiarito, Gabriele D’Amato, Graziana Colaianni, Silvia Concetta Colucci, Maria Grano, Giacomina Brunetti · 2017 · Expert Opinion on Biological Therapy
Potential role of senescence in radiation-induced damage of the aged skeleton
Abhishek Chandra, Sean S. Park, Robert J. Pignolo · 2018 · Bone
TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone
Hiroaki Saito, Andreas Sebastian Gasser, Simona Bolamperti, Miki Maeda, Levi Matthies, Katharina Jähn, Courtney L. Long, Hartmut Schlüter, Marcel Kwiatkowski, Vaibhav Saini et al. · 2019 · Nature Communications
Fat and bone: the multiperspective analysis of a close relationship
Maria Pilar Aparisi Gómez, Carmen Ayuso Benavent, Paolo Simoni, Francisco Aparisi, Giuseppe Guglielmi, Alberto Bazzocchi · 2020 · Quantitative Imaging in Medicine and Surgery
Pathological Crosstalk between Metastatic Breast Cancer Cells and the Bone Microenvironment
Jennifer Zarrer, Marie‐Therese Haider, Daniel J. Smit, Hanna Taipaleenmäki · 2020 · Biomolecules
Osteoporosis management-current and future perspectives – A systemic review
Rajamohanan Jalaja Anish, Aswathy Nair · 2024 · Journal of Orthopaedics
Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study
Joshua Stokar, Auryan Szalat · 2024 · The Journal of Clinical Endocrinology & Metabolism
Repeating Measurement of Bone Mineral Density when Monitoring with Dual-energy X-ray Absorptiometry: 2019 ISCD Official Position
David L. Kendler, Juliet Elizabeth Compston, JOHN J. CAREY, Chih‐Hsing Wu, Ammar Ibrahim, Edward Michael Lewiecki · 2019 · Journal of Clinical Densitometry
Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture
James R. Turk, Aimée M. Deaton, Jun Yin, Marina Stolina, Melanie Felx, Gabrielle Boyd, Jean-Guy Bienvenu, Aurore Varela, Martin Guillot, Gill Holdsworth et al. · 2020 · Regulatory Toxicology and Pharmacology
Mechanisms Underlying Normal Fracture Healing and Risk Factors for Delayed Healing
Cheng Cheng, Dolores Shoback · 2019 · Current Osteoporosis Reports
Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial
Erik Fink Eriksen, Roland D Chapurlat, Rogely Waite Boyce, Yifei Shi, Jacques P. Brown, S. Horlait, Donald Betah, Cesar R. Libanati, Pascale Chavassieux · 2020 · Journal of Bone and Mineral Research
Regenerating zebrafish scales express a subset of evolutionary conserved genes involved in human skeletal disease
Dylan J. M. Bergen, Qiao Tong, Ankit Shukla, Elis Newman, Jan Zethof, Mischa Lundberg, Rebecca Ryan, Scott E. Youlten, Eleftheria Zeggini, Peter Ian Croucher et al. · 2022 · BMC Biology
Advances in treatment of glucocorticoid-induced osteoporosis
Emory Hsu, Mark S. Nanes · 2017 · Current Opinion in Endocrinology Diabetes and Obesity
Developments in rare bone diseases and mineral disorders
Siobhán Bacon, Rachel Katherine Crowley · 2017 · Therapeutic Advances in Chronic Disease
Updates in CKD-Associated Osteoporosis
Pascale Khairallah, Thomas L. Nickolas · 2018 · Current Osteoporosis Reports
Rethinking Bone Disease in Kidney Disease
Matthew J. Damasiewicz, Thomas L. Nickolas · 2018 · JBMR Plus
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
Michael R. McClung, MA Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente Lomholt Langdahl, Judy Maddox, Yifei Shi, Maria Rojeski, Paul D Meisner, Andreas Grauer · 2020 · Osteoporosis International
Romosozumab: A Review in Postmenopausal Osteoporosis
Julia Paik, Lesley J. Scott · 2020 · Drugs & Aging
Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin
Tilman D. Rachner, Lorenz Christian Hofbauer, Andy Göbel, Elena A. Tsourdi · 2018 · Journal of Molecular Endocrinology
Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview
Yoshiya Tanaka · 2021 · Journal of Clinical Medicine
Pathogenesis and Treatment of Myeloma-Related Bone Disease
Yuh-Ching Gau, Tsung-Jang Yeh, Chin-Mu Hsu, S. Y. Hsiao, Hui-Hua Hsiao · 2022 · International Journal of Molecular Sciences
Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study
Ayako Tominaga, K. Wada, Ken Okazaki, Hideharu Nishi, Yasushi Terayama, Yoshiharu Kato · 2021 · Osteoporosis International
Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies
Mikkel Bo Brent · 2023 · Pharmacology & Therapeutics
Osteoblast as a target of anti-osteoporotic treatment
Addolorata Corrado, Eliana Rita Sanpaolo, Silvana Di Bello, Francesco Paolo Cantatore · 2017 · Postgraduate Medicine
Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations
Stergios A. Pοlyzos, Athanasios D. Anastasilakis, Zoe A. Efstathiadou, Maria P. Yavropoulou, Polyzois Makras · 2021 · Maturitas
The Role of BMP Signaling in Osteoclast Regulation
Brian P. Heubel, Anja Nohe · 2021 · Journal of Developmental Biology
Management of fracture risk in CKD—traditional and novel approaches
Mathias Loberg Haarhaus, Louise Aaltonen, Daniel Cejka, Mario Gennaro Cozzolino, Renate T. de Jongh, Patrick C. D’Haese, Pieter Evenepoel, Marie‐Hélène Lafage‐Proust, Sandro Mazzaferro, Eugene Vincent McCloskey et al. · 2022 · Clinical Kidney Journal